Alzheimer's Disease: A Clinical and Basic Science Review

Alzheimer’s disease (AD) is the most common cause of dementia in older adults and an important public health problem. The purpose of this review article is to provide a brief introduction to AD and the related concept of mild cognitive impairment (MCI). The article emphasizes clinical and neurobiological aspects of AD and MCI that medical students should be familiar with. In addition, the article describes advances in the use of biomarkers for diagnosis of AD and highlights ongoing efforts to develop novel therapies.

[1]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[2]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[3]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[4]  D. Mann,et al.  Pyramidal nerve cell loss in Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[5]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[6]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[7]  Igor O. Korolev,et al.  Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: A DTI/FDG‐PET Study , 2012, Human brain mapping.

[8]  S. Riedel-Heller,et al.  Mild cognitive impairment , 2006, Neurology.

[9]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[10]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[11]  Mary Ganguli,et al.  About a peculiar disease of the cerebral cortex: Alzheimer's original case revisited. , 2005, Psychiatry (Edgmont (Pa. : Township)).

[12]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[13]  S. Mori,et al.  Principles of Diffusion Tensor Imaging and Its Applications to Basic Neuroscience Research , 2006, Neuron.

[14]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[15]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[16]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[17]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[18]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[19]  Jing He,et al.  Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. , 2009, Archives of neurology.

[20]  Diederick E Grobbee,et al.  Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study , 1995, BMJ.

[21]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[22]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[23]  Yaakov Stern,et al.  Frequency and course of mild cognitive impairment in a multiethnic community , 2008, Annals of neurology.

[24]  R. Bartha,et al.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. , 2008, Brain : a journal of neurology.

[25]  Kewei Chen,et al.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Miller,et al.  Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer's Disease and Frontotemporal Lobar Degeneration , 2008, American journal of Alzheimer's disease and other dementias.

[27]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[28]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[29]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[30]  C. Jack,et al.  Mild cognitive impairment: ten years later. , 2009, Archives of neurology.

[31]  M. Pangalos,et al.  Treatment strategies targeting amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[32]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[33]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[34]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[35]  T. Tomita.  Secretase inhibitors and modulators for Alzheimer’s disease treatment , 2009, Expert review of neurotherapeutics.

[36]  Regina Berretta,et al.  Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset , 2012, PloS one.

[37]  C. Ballard,et al.  Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease , 2013, Pharmaceuticals.

[38]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[39]  C. Jack,et al.  Patterns of atrophy differ among specific subtypes of mild cognitive impairment. , 2007, Archives of neurology.

[40]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[41]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[42]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[43]  Claus Hamann,et al.  Auguste D and Alzheimer's disease , 1997, The Lancet.

[44]  James M Provenzale,et al.  Alzheimer's disease: neuropathologic findings and recent advances in imaging. , 2004, AJR. American journal of roentgenology.

[45]  F. LaFerla,et al.  Alzheimer's disease. , 2010, The New England journal of medicine.

[46]  N. Foster,et al.  Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. , 2001, Archives of neurology.

[47]  A. Mitchell,et al.  Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[48]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[49]  R. Petersen.  MILD COGNITIVE IMPAIRMENT , 2004, Lancet.

[50]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[51]  C. Harrington,et al.  Tau-aggregation inhibitor therapy for Alzheimer's disease. , 2014, Biochemical pharmacology.

[52]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[53]  L A Beckett,et al.  Is the risk of developing Alzheimer's disease greater for women than for men? , 2001, American journal of epidemiology.

[54]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[55]  L. Schneider,et al.  Report of the task force on designing clinical trials in early (predementia) AD , 2010, Neurology.

[56]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[57]  K. Langa,et al.  Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study , 2007, Neuroepidemiology.

[58]  Mattias Ohlsson,et al.  Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease , 2012, PloS one.

[59]  Stephen M. Smith,et al.  Advances and Pitfalls in the Analysis and Interpretation of Resting-State FMRI Data , 2010, Front. Syst. Neurosci..

[60]  David C. Zhu,et al.  Alzheimer's disease and amnestic mild cognitive impairment weaken connections within the default-mode network: a multi-modal imaging study. , 2013, Journal of Alzheimer's disease : JAD.

[61]  S. Pearson,et al.  Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions. , 2014, JAMA internal medicine.

[62]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[63]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[64]  Dan Mungas,et al.  Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. , 2009, Archives of neurology.

[65]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.